FDA approved selexipag for the treatment of pulmonary hypertension

Source: Maitong 2015-12-23 recently, FDA approved the orphan drug selexipag (uptravi) for the treatment of adult pulmonary hypertension Pulmonary hypertension is a chronic progressive lung disease with poor prognosis Patients may die prematurely or need lung transplantation Selexipag is an oral IP prostacyclin receptor agonist, which can relax the smooth muscle of blood vessel wall, dilate blood vessel and reduce the pressure of pulmonary artery In a clinical trial, 1156 adult patients with pulmonary hypertension were treated with selexipag for 1.4 years (median) The results showed that the drug was safe and effective Compared with placebo, it could effectively reduce the hospitalization rate and disease deterioration risk of pulmonary hypertension Adverse reactions of selexipag include headache, diarrhea, jaw pain, nausea, myalgia, vomiting, limb pain and flushing The drug is expected to be available in the United States in early January Dr Ellis Unger points out that selexipag provides an additional treatment option for patients with pulmonary hypertension Currently, the drug is also under review in Europe, Australia, Canada, New Zealand, South Korea, Switzerland and Taiwan.